Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.6%

1 terminated/withdrawn out of 18 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

86%

6 of 7 completed trials have results

Key Signals

6 recruiting6 with results

Enrollment Performance

Analytics

N/A
7(46.7%)
Phase 1
5(33.3%)
Phase 2
3(20.0%)
15Total
N/A(7)
Phase 1(5)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT04088890Phase 1Completed

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Role: collaborator

NCT06260891Phase 2Recruiting

Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

Role: collaborator

NCT05080166Not ApplicableRecruiting

UPLYFT For Lymphoma Survivors

Role: collaborator

NCT06153797Not ApplicableActive Not Recruiting

A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors

Role: collaborator

NCT05451940Phase 1Completed

Hydroxyurea and EPO in Sickle Cell Disease

Role: collaborator

NCT05434598Not ApplicableRecruiting

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

Role: collaborator

NCT02756962Phase 2Active Not Recruiting

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Role: collaborator

NCT05507827Phase 1Active Not Recruiting

Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL

Role: collaborator

NCT06982274Phase 2Recruiting

Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia

Role: collaborator

NCT06928909Recruiting

Leukemia Adapted Protocol

Role: collaborator

NCT03755414Phase 1Completed

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Role: collaborator

NCT05139992Completed

COVID-19 Vaccine Response in Sickle Cell Disease

Role: collaborator

NCT05998824Not ApplicableCompleted

COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease

Role: collaborator

NCT06379282Not ApplicableRecruiting

Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia

Role: collaborator

NCT01898793Phase 1Terminated

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Role: collaborator

NCT04605211Not ApplicableCompleted

A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors

Role: collaborator

NCT00895154Not ApplicableCompleted

A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study

Role: collaborator

NCT03535220Unknown

The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

Role: lead

All 18 trials loaded